DDInter1149 DDInter1544
Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Mepenzolate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextropropoxyphene
Mepenzolate {u} (Compound) resembles {v} (Compound) Fexofenadine
Mepenzolate {u} (Compound) resembles {v} (Compound) Diphemanil Methylsulfate
Mepenzolate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aclidinium
Mepenzolate {u} (Compound) binds {v} (Gene) CHRM1
Mepenzolate {u} (Compound) upregulates {v} (Gene) SGCB
Mepenzolate {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Antagonists
Mepenzolate {u} (Compound) downregulates {v} (Gene) DLD
Mepenzolate {u} (Compound) causes {v} (Side Effect) Bloated feeling
Mepenzolate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indapamide
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene
Mepenzolate (Compound) resembles Fexofenadine (Compound)
Mepenzolate (Compound) resembles Diphemanil Methylsulfate (Compound)
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Mepenzolate (Compound) binds CHRM1 (Gene)
Mepenzolate (Compound) upregulates SGCB (Gene)
Mepenzolate (Compound) is included by Cholinergic Antagonists (Pharmacologic Class)
Mepenzolate (Compound) downregulates DLD (Gene)
Mepenzolate (Compound) causes Bloated feeling (Side Effect)
Mepenzolate may cause a minor interaction that can limit clinical effects when taken with Indapamide